Chikungunya Clinical Trial
Official title:
A Randomized, Observer-Blinded, Dose-Escalation Phase 1 Study to Assess the Safety and Immunogenicity of Three Different Dose Levels of a Live-Attenuated Chikungunya Virus Vaccine Candidate (VLA1553) in Healthy Volunteers Aged 18 To 45 Years
Randomized, observer-blinded, multicenter, dose-escalation Phase 1 clinical study
investigating three dose levels of VLA1553 after a single immunization.
120 study participants will be enrolled into the study to receive three different doses (30
subjects in the low and medium and 60 subjects in the high dose group). Vaccination will be
given intramuscularly on Day 0. As safety precaution, the study will begin with enrolment of
20 sentinel subjects in an open-label fashion. Thereafter, subjects will be enrolled in a
blinded, randomized manner in the three study arms.
A re-vaccination will be given at Month 6 or Month 12 to confirm that a single vaccination
will be sufficient to induce high titer neutralizing antibodies and protect subjects from
CHIKV viremia.
Study participants will be followed up until 13 months after initial vaccination.
n/a
| Status | Clinical Trial | Phase | |
|---|---|---|---|
| Completed |
NCT03641339 -
Defining Skin Immunity of a Bite of Key Insect Vectors in Humans
|
N/A | |
| Completed |
NCT04440774 -
Research Study to Assess New Chikungunya and Zika Vaccines in Healthy Adults in Mexico.
|
Phase 1 | |
| Completed |
NCT05153018 -
Population Immunity AgaiNst mosquitO-borne Diseases in Vanuatu
|
N/A | |
| Active, not recruiting |
NCT04343521 -
Quantifying the Epidemiological Impact of Targeted Indoor Residual Spraying on Aedes-borne Diseases
|
Phase 3 | |
| Completed |
NCT03992872 -
Phase 2 Open-label Study of Alum-adjuvanted Chikungunya Virus-like Particle Vaccine (PXVX0317)
|
Phase 2 | |
| Completed |
NCT02831699 -
The Evaluation of Potential Zika, Chikungunya, and Dengue Infections in Mexico
|
||
| Recruiting |
NCT01099852 -
Cohort of Patients Infected by an Arbovirus
|
||
| Completed |
NCT06257810 -
Impact of Differential and Systematic Diagnosis of Dengue, Chikungunya and Malaria on Patient Management and Antibiotic Use in West Africa
|
Phase 4 | |
| Suspended |
NCT05218304 -
Baromètre Santé Adulte 2021-2022
|
N/A | |
| Recruiting |
NCT04615364 -
Genetic Evolution of Arboviruses in New Caledonia Between 1995 and 2024 and Impact of Wolbachia
|
||
| Completed |
NCT04650399 -
A Multicenter Study to Evaluate Safety and Immunogenicity of a Live-attenuated Chikungunya Vaccine in Adolescents
|
Phase 3 | |
| Not yet recruiting |
NCT04672577 -
Infection Tracking in Travellers. The Project Aims to Identify Profiles of Travel-associated Illness and to Follow up on Long-term Sequelae of Arboviral Infections and Malaria
|
||
| Completed |
NCT04434846 -
Sylvatic Transmission of Zika, Dengue, and Chikungunya Viruses in Thailand and Cambodia
|
||
| Recruiting |
NCT04838574 -
Post-Chikungunya Rheumatism - Rheumatology Follow-up of Patients After 15 Years
|
||
| Recruiting |
NCT04619823 -
Virological and Immunological Determinants of Arbovirus Infection in New Caledonia
|
N/A | |
| Completed |
NCT03101111 -
Study of a Live Attenuated Chikungunya Vaccine in a Previously Epidemic Area
|
Phase 2 | |
| Completed |
NCT02463968 -
Chikungunya Arthritis in the Americas
|
N/A | |
| Active, not recruiting |
NCT04566484 -
Seamless Controlled Trial To Evaluate Safety And Immunogenicity of Chikungunya Vaccine in LatinAmerica and Asia
|
Phase 2/Phase 3 | |
| Completed |
NCT04603131 -
Clinical Trial to Evaluate the Immunogenicity of Chikungunya Vaccine
|
Phase 1 |